Type of Spiritual Experience
A description of the experience
Raloxifene (marketed as Evista ) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer
Common adverse events considered to be drug-related were hot flashes and leg cramps.
Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes. Raloxifene is a teratogenic drug, i.e., can cause developmental abnormalities such as birth defects.
Black box warnings were added to the label of raloxifene in 2007 warning of increased risk of death due to stroke for postmenopausal women with documented coronary heart disease or at increased risk for major coronary events, as well as increased risks for deep vein thrombosis and pulmonary embolism
On Feb, 7, 2016: 1,158 people reported to have side effects when taking Raloxifene hydrochloride. Among them, 6 people (0.52%) have Hallucination.
On Feb, 7, 2016: 1,158 people reported to have side effects when taking Raloxifene hydrochloride. Among them, 21 people (1.81%) have Death.
Time on Raloxifene hydrochloride when people have Death :
|< 1 month||1 - 6 months||6 - 12 months||1 - 2 years||2 - 5 years||5 - 10 years||10+ years|
Age of people who have Death when taking Raloxifene hydrochloride :
Top conditions involved for these people :
- Osteoporosis postmenopausal (10 people, 47.62%)
- Osteoporosis (8 people, 38.10%)